Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Ocuphire Pharma Inc (OCUP)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Ocuphire Pharma's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.870 -0.070    -3.61%
14:11:46 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 125,803
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.850 - 1.950
Ocuphire Pharma 1.870 -0.070 -3.61%

OCUP Recent Sentiments

 
This page contains information on users’ sentiments for the Ocuphire Pharma Inc stock, which are displayed both on charts of different periods of time and on a detailed table.
BearishBullish
Start Date Username Call Open Rate End Date Chg. %
May 08, 2024 christian autiero   1.870 0.00%
May 07, 2024 Laura B   1.970 -5.08%
May 07, 2024 Kostandin Llupi   2.010 -6.97%
May 03, 2024 Kostandin Llupi   1.970 May 06, 2024 @ 2.070 +5.08%
May 03, 2024 Daniela kat   2.010 -6.97%
May 02, 2024 Luca Zucchini   1.859 +0.59%
May 02, 2024 Massimo Stradi   1.885 +0.80%
May 02, 2024 Sergio Caccialanza   1.855 +0.81%
May 02, 2024 Franco mo   1.762 +6.13%
May 02, 2024 Fabrizio Trevisan   1.687 +10.85%
Apr 29, 2024 一義 高島   1.610 Apr 29, 2024 @ 1.693 +5.16%
Apr 22, 2024 Massimo Stradi   1.540 Apr 23, 2024 @ 1.571 +2.01%
Apr 18, 2024 Leo Messi   1.750 Apr 22, 2024 @ 1.518 -13.26%
Apr 16, 2024 stefano franco   1.710 +9.36%
Apr 08, 2024 kermit dekikker   1.850 May 03, 2024 @ 1.990 -7.57%
Mar 27, 2024 Daniele Dardi   2.010 Apr 19, 2024 @ 1.655 -17.66%
Mar 15, 2024 一義 高島   1.830 Mar 18, 2024 @ 1.960 +7.10%
Mar 11, 2024 Cristina Federico   2.050 Apr 05, 2024 @ 1.910 -6.83%
Mar 08, 2024 Massimo Stradi   2.050 Mar 12, 2024 @ 2.130 +3.90%
Mar 07, 2024 simone de giorgi   2.380 Mar 29, 2024 @ 2.010 -15.55%
Feb 20, 2024 stefano franco   2.590 Mar 15, 2024 @ 1.900 -26.64%
Jan 31, 2024 Domenico De Caria   2.715 Feb 23, 2024 @ 2.500 -7.92%
Jan 19, 2024 Francesco Berto   2.710 Jan 22, 2024 @ 2.750 +1.48%
Dec 06, 2023 Massimo Stradi   2.780 Dec 26, 2023 @ 2.888 +3.88%
Nov 30, 2023 עידו לזרוביץ   2.960 Dec 22, 2023 @ 2.750 -7.09%
Nov 27, 2023 Elisabetta Frate   2.713 Dec 22, 2023 @ 2.750 +1.36%
Nov 02, 2023 Артем Драч   2.745 Nov 30, 2023 @ 2.740 -0.18%
Oct 11, 2023 Fahad Almoamen   3.365 Nov 30, 2023 @ 2.740 -18.57%
Oct 03, 2023 Massimo Stradi   3.396 Nov 30, 2023 @ 2.740 -19.32%
Sep 27, 2023 stefano franco   3.800 Nov 30, 2023 @ 2.740 -27.89%
Sep 27, 2023 William Neta   4.145 Nov 30, 2023 @ 2.740 -33.90%
Sep 13, 2023 רונן בן   4.050 Nov 30, 2023 @ 2.740 -32.35%
Jul 14, 2023 JAY MAG   4.150 Nov 30, 2023 @ 2.740 -33.98%
Jun 30, 2023 perins Tursev   4.180 Nov 30, 2023 @ 2.740 -34.45%
May 15, 2023 Majdy Alsayed   4.868 Jul 13, 2023 @ 4.230 -13.11%
May 09, 2023 晋利 井口   5.625 Nov 30, 2023 @ 2.740 -51.29%
May 08, 2023 דקל ענאקי   5.845 Nov 30, 2023 @ 2.740 -53.12%
Apr 26, 2023 Erich Chudy   5.170 May 09, 2023 @ 5.810 +12.38%
Apr 24, 2023 Alessio Oertel   5.130 May 23, 2023 @ 4.140 -19.30%
Apr 21, 2023 Roman Schulze   4.730 May 25, 2023 @ 3.651 +22.81%
Apr 21, 2023 Massimo Stradi   4.710 Apr 25, 2023 @ 4.950 +5.10%
Apr 18, 2023 Ahmed D   5.930 Nov 30, 2023 @ 2.740 -53.79%
Apr 11, 2023 Naif Alfahadi   5.600 May 09, 2023 @ 5.810 +3.75%
Apr 04, 2023 지훈 권   4.820 May 09, 2023 @ 5.810 +20.54%
Mar 21, 2023 stefano franco   3.750 Apr 14, 2023 @ 5.360 +42.93%
Mar 07, 2023 Alessandro Acciardi   3.705 Mar 13, 2023 @ 3.620 -2.29%
Feb 13, 2023 Robbert Kuipers   3.700 Mar 10, 2023 @ 3.400 -8.11%
Jan 26, 2023 Lilia Litvin   3.005 Jan 28, 2023 @ 3.410 +13.48%
Dec 28, 2022 Roberto Marini   3.052 Jan 20, 2023 @ 3.850 +26.15%
Nov 08, 2022 Cruzeiro dos Santos   2.670 Nov 14, 2022 @ 2.780 -4.12%
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

OCUP Comments

Write your thoughts about Ocuphire Pharma Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Anthony Morrow
Note7Creole Nov 25, 2021 7:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nice
Joe Jordan
Joe Jordan Nov 25, 2021 12:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Analyst Matthew Caufield set a price target of $26 on the stock, outlining four reasons for doing so. The company's shares are currently 38% above Tuesday's close at $4.81 but initially rose to a high of $5.50. The first of the four reasons for the rating is Ocuphire's phase 3 MIRA-2 trial's positive topline results for Nyxol. The analyst said that it presents an "opportune timing to get into the name prior to further program validation," which it expects in the near term. He also said a key differentiation of using Nyxol was another positive for the stock, adding that Ocuphire's APX3330 treatment for diabetic retinopathy is undervalued. "With Ocuphire completing a reverse merger with legacy oncology platform Rexahn Pharmaceuticals, and listing on NASDAQ in November 2020, we maintain invest
Jun 30, 2021 8:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
BLIN is next MRIN
Mr Intolerant
Mr Intolerant Mar 16, 2021 1:32PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I like $12. Holding until then at least. Good company.
Dong ThreeThousand
Dong ThreeThousand Mar 15, 2021 6:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Ocuphire Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint
Joe Jordan
Joe Jordan Feb 20, 2021 2:07AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any target price?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email